Kilitch Operating Income from 2010 to 2024

KILITCH Stock   315.60  4.95  1.59%   
Kilitch Drugs' Operating Income is decreasing with very volatile movements from year to year. Operating Income is estimated to finish at about 218.5 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Kilitch Drugs Limited generates from its operations. View All Fundamentals
 
Operating Income  
First Reported
2012-06-30
Previous Quarter
61.5 M
Current Value
8.1 M
Quarterly Volatility
33.8 M
 
Yuan Drop
 
Covid
Check Kilitch Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kilitch Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 32.6 M, Interest Expense of 63.4 M or Selling General Administrative of 25 M, as well as many indicators such as . Kilitch financial statements analysis is a perfect complement when working with Kilitch Drugs Valuation or Volatility modules.
  
This module can also supplement various Kilitch Drugs Technical models . Check out the analysis of Kilitch Drugs Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Kilitch Stock

Kilitch Drugs financial ratios help investors to determine whether Kilitch Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kilitch with respect to the benefits of owning Kilitch Drugs security.